Skip to main content

Table 1 Baseline characteristics of 149 patients

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Characteristics

Number (%)

Median (range)

Age (years)

 

61 (36–75)

  ≤ 65

95 (63.8%)

 

 >65

54 (36.2%)

 

Sex

 Male

111 (74.5%)

 

 Female

38 (25.5%)

 

Smoking

 Never

60 (40.3%)

 

 Ever

89 (59.7%)

 

ECOG PS

 0

73 (49.0%)

 

 1

76 (51.0%)

 

Histological type

 Adenocarcinoma

94 (63.1%)

 

 Squamous

55 (36.9%)

 

Lesion type

 Central

78 (52.3%)

 

 Peripheral

71 (47.7%)

 

Clinical stage

 IIIB

69 (46.3%)

 

 IV

80 (53.7%)

 

CEA

 Normal

95 (63.8%)

 

 Increased

54 (36.2%)

 

Albumin

 Decreased

50 (33.6%)

 

 Normal

99 (66.4%)

 

WBC (× 109/L)

 

7.6 (3.6–12)

LMR

 

3.25 (0.98–12.5)

NLR

 

2.78 (1.05–8.14)

PLR

 

143 (35–352)

SUVmax

 

11.8 (3.3–28.5)

  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, CEA carcinoembryonic antigen, WBC white blood cell, LMR lymphocyte-monocyte ratio, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, SUVmax maximum standardized uptake value